<DOC>
	<DOCNO>NCT00104468</DOCNO>
	<brief_summary>This phase I , single-arm , open-label , multi-center study rise dos Troxatyl™ whose purpose determine safety , tolerance , pharmacokinetics , establish recommend infusion schedule Troxatyl™ .</brief_summary>
	<brief_title>Study Troxatyl™ Administered Continuous Infusion Subjects With Refractory Acute Myelogenous Leukemia ( AML )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Troxacitabine</mesh_term>
	<criteria>Confirmed diagnosis acute myelogenous leukemia ( AML ) refractory prior therapy and/or unlikely benefit know therapy . Subjects must adequate organ immune function indicate follow laboratory value : *Creatinine clearance ≥5 L/hr ( 83mL/min ) , *Total Bilirubin ≤2.0 mg/dL ( ≤34.2 µmol/L ) , *AST ( SGOT ) ALT ( SGPT ) ≤3 x ULN Clinical evidence active central nervous system ( CNS ) leukemic involvement Active uncontrolled infection Uncontrolled medical problem unrelated malignancy impair ability give inform consent unacceptably reduce safety propose treatment Neurologic psychiatric disorder would interfere informed consent study followup Known suspect intolerance hypersensitivity investigational new drug closely related compound like lamivudine , and/or recent history alcohol substance abuse . Also eligible subject use another investigational agent participate clinical trial within last 14 day prior enrollment . Females positive pregnancy test screen subject previously enrol study subsequently withdraw .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Single-arm , open-label , multi-center , dose escalation , continuous infusion , multi-dose , acute myeloid leukemia</keyword>
	<keyword>Acute myelogenous leukemia ( AML ) refractory prior therapy and/or unlikely benefit know therapy</keyword>
</DOC>